Rain Therapeutics Inc. (RAIN): Price and Financial Metrics
RAIN Price/Volume Stats
| Current price | $0.85 | 52-week high | $14.48 |
| Prev. close | $0.85 | 52-week low | $0.82 |
| Day low | $0.84 | Volume | 138,929 |
| Day high | $0.87 | Avg. volume | 707,267 |
| 50-day MA | $1.09 | Dividend yield | N/A |
| 200-day MA | $5.31 | Market Cap | 30.92M |
RAIN Stock Price Chart Interactive Chart >
Rain Therapeutics Inc. (RAIN) Company Bio
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
Latest RAIN News From Around the Web
Below are the latest news stories about RAIN ONCOLOGY INC that investors may wish to consider to help them evaluate RAIN as an investment opportunity.
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3 million expected to provide runway into year-end 2026 – – Management to host conference call and webcast today at 2:00 pm PT/5:00 pm ET – NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain |
Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”) today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results. Conference Call and Webcast Details: Date: August 10, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers: |
Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Rain Oncology Provides Company Update and Outlines Strategic Priorities of Milademetan Clinical Programs– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial – – Evaluation of outcomes from the MANTRA Phase 3 milademetan trial in dedifferentiated liposarcoma (DD LPS) are ongoing with data and findings to be presented at a medical conference in 4Q23 – – Company continuing to evaluate opportunities for expansion of its pipeline across precision oncology strategies – – Overall workforce reduction |
4 big analyst cuts: Apple loses buy rating on slack iPhone demandHere is your Pro Recap of the biggest analyst cuts you may have missed since yesterday: downgrades for Apple, Revolve, Rain Therapeutics, and Intercept Pharmaceuticals. Loop Capital downgraded Apple (NASDAQ:AAPL) to Hold from Buy with a price target of $180.00. The firm sees a material downside risk to revenue (both iPhone and overall) estimates for Q3, relative to both the company’s guidance and Street forecasts. |
RAIN Price Returns
| 1-mo | -16.67% |
| 3-mo | -30.89% |
| 6-mo | -90.31% |
| 1-year | -86.90% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -89.38% |
| 2022 | -37.89% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...